Asgard Therapeutics is aiming to advance cancer immunotherapies by developing a paradigm-shifting gene therapy – Trojan DC – a technology that lent itself well to being both a personalized and an off-the-shelf therapy. Asgard is developing the world’s first cancer immunotherapy based on direct cell reprogramming, forcing cancer cells to present their own antigens to the immune system and by doing so unleashing the immune system against themselves. Asgard’s immunotherapy candidate, Trojan DC, is in a pre-clinical stage.